# US 2026/0097067 A1 · Hydroxypropyl beta-cyclodextrin compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097067 A1
- Document ID: US20260097067A1
- Status: Published application
- Kind: A1
- Application number: 19/406,305
- Filed: 2025-12-02
- Published: 2026-04-09
- Earliest claimed: 2015-06-10
- Assignees: Mandos LLC
- Applicants: Mandos LLC
- Inventors: Bernardus Nicolaas Machielse; Allan Darling
- Web page: https://patentgrep.com/patent/US20260097067A1

## CPC

- A61K 31/724: Cyclodextrins
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

## Claims

### Claim 1

A method of treating Niemann Pick in a human patient in need thereof comprising administering a composition comprising a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, wherein: the mixture comprises unsubstituted beta-cyclodextrin (“DS-0”), beta-cyclodextrin substituted with one hydroxypropyl group (“DS-1”), and from 5% to 25% beta-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”).

### Claim 2 (depends on 1)

The method of claim 1, wherein less than 3% of the mixture comprises DS-0 and DS-1, collectively.

### Claim 3 (depends on 1)

The method of claim 1, wherein less than 2% of the mixture comprises DS-0 and DS-1, collectively.

### Claim 4 (depends on 1)

The method of claim 1, wherein the mixture comprises at least 8% DS-6.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mixture comprises from 8% to 22% DS-6.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mixture comprises no more than 15% DS-6.

### Claim 7 (depends on 1)

The method of claim 1, wherein less than 2% of the mixture is DS-0.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mixture has an average molar substitution (“MS”) in the range of 0.40-0.80.

### Claim 9 (depends on 1)

The method of claim 1, wherein the mixture has an average degree of substitution (DSa″) of about 3 to about 7.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition comprises no more than 0.5% propylene glycol.

### Claim 11 (depends on 1)

The method of claim 1, wherein less than 4% of the mixture comprises DS-1.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition comprises no more than 1 ppm propylene oxide.

### Claim 13 (depends on 1)

The method of claim 1, wherein the total amount of other unspecified impurities in the composition is less than or equal to 0.05% as measured by HPLC.

### Claim 14 (depends on 1)

The method of claim 1, wherein the composition has a concentration of about 10 mg/mL to about 200 mg/mL.

### Claim 15 (depends on 1)

The method of claim 1, wherein the patient is a pediatric patient.

### Claim 16 (depends on 1)

The method of claim 1, wherein the patient is an adult patient.

### Claim 17 (depends on 1)

The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable diluent.

### Claim 18 (depends on 1)

The method of claim 1, wherein the composition solubilizes lipids in an aqueous medium.

### Claim 19 (depends on 18)

The method of claim 18, wherein lipids that are solubilized comprise unesterified or esterified cholesterol.

### Claim 20 (depends on 19)

The method of claim 19, wherein the solubilization is determined by UV spectrometry or by HPLC.

### Claim 21 (depends on 1)

The composition of claim 1, wherein about 200 mg of the composition is capable of solubilizing at least 2 mg of unesterified cholesterol in distilled water at room temperature.

### Claim 22

A method of treating Niemann Pick in a human patient in need thereof comprising administering a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, wherein: the mixture comprises unsubstituted beta-cyclodextrin (“DS-0”), beta-cyclodextrin substituted with one hydroxypropyl group (“DS-1”), and at least 5% beta-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”).

### Claim 23 (depends on 22)

The method of claim 22, wherein the mixture comprises at least 10% DS-6.

### Claim 24 (depends on 22)

The method of claim 22, wherein the mixture comprises at least 13% DS-6.

### Claim 25 (depends on 22)

The method of claim 22, wherein the mixture comprises at least 15% DS-6.

### Claim 26 (depends on 22)

The method of claim 22, wherein less than 2% of the mixture comprises DS-0.

### Claim 27 (depends on 22)

The method of claim 22, wherein less than 4% of the mixture comprises DS-1.

### Claim 28

A method of treating Niemann Pick in a human patient in need thereof comprising administering a mixture of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, wherein: the mixture comprises unsubstituted beta-cyclodextrin (“DS-0”), beta-cyclodextrin substituted with one hydroxypropyl group (“DS-1”), and no more than 25% beta-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”).

### Claim 29 (depends on 28)

The method of claim 28, wherein less than 2% of the mixture comprises DS-0.

### Claim 30 (depends on 28)

The method of claim 28, wherein less than 4% of the mixture comprises DS-1.
